Key result
French intensive care panel issues 21 recommendations for managing pediatric non-postoperative supraventricular tachycardia.
Why the study?
Although many efficient drugs are available for SVT treatment in infants, a careful risk-benefit analysis is needed to guide the correct antiarrhythmic drug choice.
Supraventricular tachycardia (SVT), being atrioventricular re-entry the underlying mechanism, is the most frequent tachyarrhythmia requiring a medical treatment in infants with no cardiac disease. The acute treatment of a single episode of SVT has generally an excellent prognosis. An antiarrhythmic prophylaxis of SVT recurrences is usually recommended during the first year of life. Although many efficient drugs are available for the SVT treatment, a careful risk-benefit analysis of each single case should suggest the correct drug choice.
No takes yet. Share an insight, caveat, or question.
Tavera et al. (2010) conducted a review in Supraventricular tachycardia (SVT). Clinical practice guidelines was evaluated. An expert panel from the French Intensive Care Society and GFRUP formulated 21 clinical recommendations for the diagnosis, evaluation, and specific management of pediatric non-post-operative supraventricular tachycardia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: